Amneal Pharmaceuticals Files 8-K on Financials
Ticker: AMRX · Form: 8-K · Filed: Jan 15, 2025 · CIK: 1723128
Sentiment: neutral
Topics: financial-results, regulation-fd, disclosure
Related Tickers: AMRX
TL;DR
AMRX dropped an 8-K on Jan 15th detailing financial results - check it out.
AI Summary
Amneal Pharmaceuticals, Inc. filed an 8-K on January 15, 2025, to report results of operations and financial condition, as well as a Regulation FD disclosure. The filing details the company's financial performance and any material information that may affect its stock price.
Why It Matters
This filing provides investors with crucial updates on Amneal Pharmaceuticals' financial health and operational performance, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine filing to report financial results and disclosures, not indicating any immediate or significant new risks.
Key Players & Entities
- Amneal Pharmaceuticals, Inc. (company) — Registrant
- January 15, 2025 (date) — Date of Report
- 001-38485 (company) — Commission File Number
- 93-4225266 (company) — IRS Employer Identification No.
- 400 Crossing Blvd Bridgewater, NJ 08807 (company) — Principal executive offices address
- (908) 947-3120 (company) — Registrant's telephone number
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates it is for 'Results of Operations and Financial Condition' but does not provide specific figures within the provided text.
What is the purpose of the Regulation FD Disclosure mentioned?
The Regulation FD Disclosure is intended to ensure that material information is broadly disseminated to the public, preventing selective disclosure.
When was Amneal Pharmaceuticals, Inc. incorporated?
The company was incorporated in Delaware, as indicated by the filing.
What is Amneal Pharmaceuticals' primary business classification?
Amneal Pharmaceuticals is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
Is there any information about former company names or addresses?
The filing notes a former company name of 'Atlas Holdings, Inc.' with a date of name change on '20171117'.
Filing Stats: 1,492 words · 6 min read · ~5 pages · Grade level 16.6 · Accepted 2025-01-15 06:14:12
Key Financial Figures
- $0.01 — stered Class A Common Stock, par value $0.01 per share AMRX The Nasdaq Stock Market
- $2.70 billion — 4 to be approximately 4x. Net revenue $2.70 billion - $2.80 billion Adjusted EBITDA (1)
- $2.80 billion — ately 4x. Net revenue $2.70 billion - $2.80 billion Adjusted EBITDA (1) $610 million - $
- $610 million — - $2.80 billion Adjusted EBITDA (1) $610 million - $630 million Adjusted diluted EPS (
- $630 million — n Adjusted EBITDA (1) $610 million - $630 million Adjusted diluted EPS (2) $0.57 - $0.
- $0.57 — 630 million Adjusted diluted EPS (2) $0.57 - $0.63 Operating cash flow (3) $280
- $0.63 — ion Adjusted diluted EPS (2) $0.57 - $0.63 Operating cash flow (3) $280 million
- $280 million — 0.57 - $0.63 Operating cash flow (3) $280 million - $320 million Capital expenditures $
- $320 million — Operating cash flow (3) $280 million - $320 million Capital expenditures $60 million - $7
- $60 million — n - $320 million Capital expenditures $60 million - $70 million (1) Includes 100% of Ad
- $70 million — on Capital expenditures $60 million - $70 million (1) Includes 100% of Adjusted EBITDA
Filing Documents
- amrx-20250115.htm (8-K) — 36KB
- 0001723128-25-000005.txt ( ) — 161KB
- amrx-20250115.xsd (EX-101.SCH) — 2KB
- amrx-20250115_lab.xml (EX-101.LAB) — 21KB
- amrx-20250115_pre.xml (EX-101.PRE) — 12KB
- amrx-20250115_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. In connection with a presentation to be made at an investor conference on January 15, 2025, Amneal Pharmaceuticals, Inc., a Delaware corporation (the "Company"), intends to announce that it expects to meet o r exceed its 2024 full year financial guidance. This guidance, in the table below, was announced on November 8, 2024 during the Company ' s third quarter investor call. The Company expects to meet its net revenue, adjusted EBITDA, and adjusted diluted EPS guidance, exceed its operating cash flow guidance, and exceed (incur less than) its capital expenditures guidance. The Company also intends to announce that it estimates its net leverage as of December 31, 2024 to be approximately 4x. Net revenue $2.70 billion - $2.80 billion Adjusted EBITDA (1) $610 million - $630 million Adjusted diluted EPS (2) $0.57 - $0.63 Operating cash flow (3) $280 million - $320 million Capital expenditures $60 million - $70 million (1) Includes 100% of Adjusted EBITDA from the AvKARE acquisition. (2) Accounts for 35% non-controlling interest in AvKARE. Guidance assumed approximately 320 million weighted-average diluted shares outstanding for the year ended December 31, 2024. (3) Does not contemplate one time and non-recurring items such as legal settlements and other discrete items. The Company's 2024 estimates are based on management's current expectations, including with respect to prescription trends and pricing levels. The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). The Company cannot provide a reconciliation between the expected non-GAAP measures and the most directly comparable measures in accordance with GAAP for the period reflected above without unreasonable efforts because of the unavailability at this time of certain significant items required for the reconciliation. The items include, but are not
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure The disclosure in Item 2.02 hereof is incorporated by reference into this item 7.01.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 15, 2025 AMNEAL PHARMACEUTICALS, INC. By: /s/ Anastasios Konidaris Name: Anastasios Konidaris Title: Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)